July 8,Stockholm, SmartCella Holding AB Announces Completion of Approximately EUR 50 Million Financing to Accelerate Extroducer's Growth and Support Its Commercialization and the Company’s Cell and mRNA Business.This financingSupported by existing large institutional investors such as Fjärde AP fonden, AMF Pension, and SEB Stiftelsen, as well as new long-term strategic investors AstraZeneca (committing to purchase approximately half of the shares) and new large institutional investors Handelsbanken Fonder and RoosGruppen AB, with a pre-tax valuation of approximately 500 million euros.
SmartCella is a global innovative biotechnology company with the vision of combining novel delivery platforms (such as the FDA-approved Extroducer) with the development of cutting-edge cell andmRNACombined with therapy. The team, consisting of global scientists, innovators, and dreamers, is committed to shaping the future of targeted medicine through innovative and reliable clinical data, and is dedicated to making targeted medicine a reality for many.Christian Kinch and Thomas von Koch remain the main shareholders (through Swiss Investment Bank Holding Company). This financing is part of SmartCella's overall strategic development and future validation, which includes continuous investment in organization and infrastructure, as well as increased commercialization and marketing efforts.Another component of the strategy is the previously announced new members of the SmartCella board, including Regina Fritsche Danielson (Senior Vice President at AstraZeneca and Global Head of Cardiovascular, Renal, and Metabolic Diseases Research and Early Development), Anna Martling (Professor of Surgery at Karolinska Institutet and Scientific Director of Life Sciences), and Claude Dartiguelongue (former executive at Lonza, Thermo Fisher Scientific, and Becton Dickinson and Company).Christian Kinch, founder and chairman of SmartCella, said:"We are very grateful for the strong support from both existing and new investors in SmartCella. We have a robust shareholder base, including highly professional investors and industry and technology leaders focused on science, such as AstraZeneca. The backing from our investors highlights their confidence in our business model, our team, and our potential to drive revolutionary change in the treatment of some of the world’s most severe diseases. SmartCella represents a compelling investment opportunity with an integrated business model that combines science, sustainability, and impact. SmartCella is truly committed to advancing a healthier future."SmartCella CEO Niklas Prager said:"We operate in the most exciting and attractive areas of biotechnology. Cell and gene therapy are currently the hottest fields in biotech research and investment, but SmartCella remains a hidden gem. With new funding, we will continue to build our organization and drive accelerated growth. We will focus particularly on advancing the commercialization of Extroducer, which I believe is one of the most groundbreaking innovations in targeted delivery solutions, capable of delivering treatment directly into hard-to-reach tumors or organs. The combination of Extroducer with our world-class research and expertise in cell and mRNA therapies makes SmartCella stand out. This financing is a milestone event for us – and our journey has just begun."Follow the official account below to explore the world with you!
